Biodegradation of and tissue reaction to poly(<scp>DL</scp>‐lactide) microcapsules

Visscher, G. E.; Robison, R. L.; Maulding, H.V.; Fong, J. W.; Pearson, Jane E.; Argentieri, G. J.

doi:10.1002/jbm.820200510

Cited by 79 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well documented that the antigen and adjuvant doses interfere with the immune responses. Studies conducted with subcutaneous implants indicate that the physicochemical characteristics of PLA and PLGA polymers play a decisive role in the in vivo degradation time and also in the local inflammatory reaction (32,33,39). These results highlight an important aspect to be considered in the development of microspheres as carriers, i.e., the dose of polymer.…”

Section: Considerations About Plga Microsphere Biocompatibilitymentioning

confidence: 92%

“…The combination of particles with different diameters and polymer composition in the same formulation has permitted to establish the concept of the single-dose vaccine (1), which can be programmed to mimic the reinforcement dosages, inducing protection with a minimal number of administrations ( Figure 2). Finally, PLA and its copolymers have proved to be biocompatible and produce little or no local or systemic toxicity (39,40).…”

Section: Poly-lactide-co-glycolide Microspheresmentioning

confidence: 99%

See 1 more Smart Citation

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system

Lima

Júnior

1999

Braz J Med Biol Res

View full text Add to dashboard Cite

Successful vaccine application means maximum protection with minimal number of administrations. A rational development of vaccines involves studies of the nature of the antigen as well as of the adjuvant to be used to improve the immune responses. This has provided the impetus for studies to design the degradable devices and for different approaches to antigen delivery by different routes of administration. The development of controlled release systems based on polymeric devices that permit a sustained or pulsed release of encapsulated antigens has attracted much interest. Polymeric delivery systems consist of polymers that release their content continuously in a controlled manner over a period of time. The development of a biocompatible delivery system for parenteral administration offers several advantages in terms of immunoadjuvanticity over other compounds. It was found that, in contrast to other carriers, microspheres are more stable, thus permitting administration by the oral or parenteral route. In the present study, we describe the main characteristics and potentialities of this new immunoadjuvant for oral and parenteral administration. Correspondence

show abstract

Section: Considerations About Plga Microsphere Biocompatibilitymentioning

confidence: 92%

Section: Poly-lactide-co-glycolide Microspheresmentioning

confidence: 99%

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system

Lima

Júnior

1999

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…PLGA of varying molecular weight (ranging from 10 to > 100 kDa) and different lactide to glycolide molar ratios (50:50, 65 [22,23]. Poly(D,L-lactide) nanoparticles was completely degraded within 480 days, whereas the PLGA nanoparticles was degraded in 63 days.…”

Section: Effect Of Plga Properties On Drug Releasementioning

confidence: 99%

Biodegradable Poly(D,L-lactic-co-glycolic acid)-Based Micro/Nanoparticles for Sustained Release of Protein Drugs - A Review

Ansary¹,

Awang²,

Rahman³

2014

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…Microsphere technology has the capability of accomplishing these goals by achieving intracellular delivery of antimycobacterial drugs and allowing programmed controlled release over a prolonged period (24). As discussed in our previous publications, the microsphere formulations used in these studies are known to be biocompatible (26,27,28) and capable of degradation to lactic and glycolic acids by nonenzymatic reactions (24). This technology has been used for sustained delivery of various biological components, including antigens, steroids, peptides, proteins, and antibiotics (1,3,9,10,11,12,14,15,21,23,25).…”

mentioning

confidence: 99%

Treatment of Tuberculosis Using a Combination of Sustained-Release Rifampin-Loaded Microspheres and Oral Dosing with Isoniazid

Quenelle¹,

Winchester²,

Staas³

et al. 2001

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Previously, we reported on the use of rifampin-loaded microspheres to effectively treat Mycobacterium tuberculosis-infected macrophages and mice. Using similar biocompatible polymeric excipients of lactide and glycolide copolymers, we have increased the rifampin loading of small microsphere formulations (1 to 10 m) by fourfold. Improved formulations were evaluated individually and in combination with oral regimens of isoniazid for the treatment of Mycobacterium tuberculosis H37Rv-infected mice. Groups (10 mice per group) consisted of mice that received (i) oral dosages of isoniazid (25 to 0.19 mg/kg of body weight/day), (ii) two intraperitoneal injections of rifampin-loaded microspheres on days 0 and 7, (iii) a combination of small rifampin-loaded microspheres on days 0 and 7 and isoniazid orally for 25 days (12.5 to 0.39 mg/kg/day), (iv) placebo injections, and (v) no treatment. Treatment with rifampin-loaded microspheres alone resulted in significant reductions in the numbers of CFU in the lungs and spleens by day 26. A bioassay revealed that plasma rifampin levels from the microspheres exceeded the MICs by more than twofold throughout the 26-day experimental period. Susceptibility testing demonstrated continued sensitivity to rifampin during the treatment period. Whereas isoniazid alone significantly reduced the numbers of CFU for dosages ranging from 12.5 to 1.56 mg/kg, combination therapy with rifampin-loaded microspheres increased the effective range to 0.39 mg/kg. In many cases, complete elimination of CFU was obtained with the combination therapy, something not achieved with most of the single therapies. These results demonstrate the ability to use small microsphere formulations alone to achieve significant results in a murine tuberculosis model and also the ability to use them safely in combination with another antimycobacterial agent.

show abstract

Biodegradation of and tissue reaction to poly(DL‐lactide) microcapsules

Cited by 79 publications

References 17 publications

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system

Biodegradable Poly(D,L-lactic-co-glycolic acid)-Based Micro/Nanoparticles for Sustained Release of Protein Drugs - A Review

Treatment of Tuberculosis Using a Combination of Sustained-Release Rifampin-Loaded Microspheres and Oral Dosing with Isoniazid

Contact Info

Product

Resources

About